Immunoglobulin M

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 30, 2023
CD38, Hepatotoxicity, Lupus, Bevacizumab, Society, Cell death, B-cell lymphoma, Investment, IGM, DLBCL, FOLFIRI, Multiple myeloma, DR5, Food, Clinical trial, Immunoglobulin M, NHL, Immunotherapy, Exposition, G&A, NK, GAAP, Antibody, EDT, Trial of the century, Rheumatoid arthritis, Acute myeloid leukemia, Incidence, Investigational New Drug, TDCC, Patient, Cytokine release syndrome, Administration, Autoimmune disease, Immunoglobulin G, Webcast, Toxic leukoencephalopathy, Daratumumab, Research and development, Research, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Autoimmunity, Safety, Pharmaceutical industry, Vaccine, Sanofi

MOUNTAIN VIEW, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent developments.

Key Points: 
  • “Also, and perhaps most significantly, the initial clinical results from IGM-8444, our anti-death receptor 5 IgM antibody, highlight the exciting potential of IgM antibodies as agonist antibody medicines.
  • The study is designed to assess the benefit of IGM-8444 when combined with the current standard of care regimen of FOLFIRI and bevacizumab.
  • In November 2022, the Company presented preclinical results at the Society for Immunotherapy of Cancer Annual Meeting.
  • IGM will host a live conference call and webcast at 4:30 p.m. EDT today, March 30, 2023, to discuss the Company’s financial results and provide a corporate update.

IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023

Retrieved on: 
星期一, 三月 27, 2023
Webcast, Immunoglobulin M, IGM, Pharmaceutical industry, Online shopping, Risk management

MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 30, 2023.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 30, 2023.
  • In connection with the earnings release, IGM’s management team will host a live conference call and webcast at 4:30 p.m.
  • ET on Thursday, March 30, 2023, to discuss the Company’s financial results and provide a corporate update.
  • The webcast can be accessed by clicking the link: https://edge.media-server.com/mmc/p/ud83kix8 and will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website.

First Clinical Study of its Kind Shows Positive Impacts from Astaxanthin During Sport Recovery

Retrieved on: 
星期二, 三月 28, 2023
Exercise, Human, Food, Diet, DOMS, Frontiers, Antibody, Clinical trial, Immunoglobulin M, Hope, VO2 max, Astaxanthin, Inflammation, Doctor of Philosophy, Proteomics, Haematococcus, Plasma, Salmon, Running, Protein, Creatine, Cauchy stress tensor, Cytokine, Oxylipin, Female, Dietary supplement, Nutrition

The findings were especially significant for levels of IgM, the predominant antibody produced early in an immune response.

Key Points: 
  • The findings were especially significant for levels of IgM, the predominant antibody produced early in an immune response.
  • This was a unique human clinical trial that measured physiological responses to astaxanthin supplementation after intense exercise using untargeted proteomics (500 proteins across all samples) and a targeted, comprehensive panel of oxylipins and cytokines.
  • Astaxanthin cannot be synthesised by humans, so it must be consumed in the diet via food or supplements.
  • "From this study, we learned that during recovery, algae-derived astaxanthin normalizes 20 immunoglobulins in those with increased inflammation from recurrent physiological stress – runners.

Bay Area Lyme Foundation Celebrates Department of Defense CDMRP Tick-borne Disease Awardees

Retrieved on: 
星期四, 三月 23, 2023
Columbia University, Tufts University, Duke University, Biobank, Notifiable disease, Doctor of Pharmacy, Virginia Tech, Therapy, Lyme disease, Babesiosis, Frontiers, Gastrointestinal tract, Infection, COVID-19, DNA sequencing, AGS, Immunoglobulin M, PCR, MBA, Research, Immunoglobulin A, Tick, Antibody, Peptidoglycan, Veteran, Tick-Borne Disease Alliance, Johns Hopkins University, Blood transfusion, Patient, Risk, Blood, Immunoglobulin G, DVM, NIH, MBI, Skin, Vaccine, Microbiology, Doctor of Philosophy, MD

PORTOLA VALLEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, announces that two projects it has previously funded have now received Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Tick-Borne Disease awards.

Key Points: 
  • PORTOLA VALLEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, announces that two projects it has previously funded have now received Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Tick-Borne Disease awards.
  • Three of the six recently announced CDMRP awardees will be using biological samples from Bay Area Lyme Foundation’s Lyme Disease Biobank to enable their research into diagnostics and therapeutics for tick-borne diseases, including Lyme disease—which infects half a million people each year.
  • Peter Gwynne, research assistant professor in Hu's lab, was a Bay Area Lyme Foundation ELA winner in 2022 and has used samples from the Lyme Disease Biobank.
  • Jutras was a Bay Area Lyme Foundation ELA winner in 2021 and his lab will be using samples from the Lyme Biobank to validate their novel diagnostics.

IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference

Retrieved on: 
星期四, 二月 2, 2023
Conference, Immunoglobulin M, IGM, EST, Webcast, Guggenheim, Pharmaceutical industry, Online shopping

MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on Thursday, February 9, 2023, at 1:35 p.m. EST in New York.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on Thursday, February 9, 2023, at 1:35 p.m. EST in New York.
  • A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations.
  • A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

Retrieved on: 
星期二, 一月 17, 2023
Cell, Immunoglobulin M, Trial of the century, Pharmacokinetics, Safety, IGM, NK, Patient, Cancer, Clinical trial, Antibody, Vaccine

The multicenter, open-label, dose escalation Phase 1 clinical trial will evaluate IGM-7354 intravenously administered as a monotherapy in patients with relapsed and/or refractory solid tumor cancers.

Key Points: 
  • The multicenter, open-label, dose escalation Phase 1 clinical trial will evaluate IGM-7354 intravenously administered as a monotherapy in patients with relapsed and/or refractory solid tumor cancers.
  • The key objectives of this trial are to provide an initial assessment of pharmacokinetics, safety and immune cell proliferation.
  • The Company may also decide to pursue combination studies with CAR-T or CAR-NK cells with a partner.
  • “The initiation of this clinical trial is another significant milestone in IGM’s development, as it is the first clinical study of an IgM targeted immune cytokine,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Retrieved on: 
星期一, 一月 9, 2023
Immunoglobulin M, Failure, Bevacizumab, DR5, PFS, FOLFIRI, IGM, Patient, KRAS, Liver disease, Liver, Immunoglobulin G, TNF, Hepatotoxicity, Vaccine, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, and announced plans for a new randomized combination trial in patients with metastatic colorectal cancer.

Key Points: 
  • Specifically, there was no drug related clinically significant hepatotoxicity, with only grade 1 and grade 2 transient liver enzyme elevations observed.
  • Responses occurred in patients with KRAS wild type and mutated tumors and in patients with or without liver metastases.
  • “We are very pleased with the initial results observed with IGM-8444,” said Chris Takimoto, M.D., Ph.D., F.A.C.P., Chief Medical Officer of IGM Biosciences.
  • These responses, especially in patients who have previously failed chemotherapy, are very encouraging and give us confidence in proceeding to further clinical development with FOLFIRI and other combination agents.

IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
星期二, 一月 3, 2023
Conference, IGM, Immunoglobulin M, Webcast, Pharmaceutical industry, Online shopping

MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.
  • A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations.
  • A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Retrieved on: 
星期一, 十二月 12, 2022
Epitope, Security (finance), Bacteria, O11, Sale, ODD, Neutralizing antibody, National Institutes of Health, CF, Immunoglobulin G, Cystic fibrosis, Infection, Immunoglobulin M, COVID-19, Urinary tract infection, European Medicines Agency, EMA, Prevalence, S. aureus, US Foods, FDA, HAP, Safety, Staphylococcus aureus, CFTR, Inhalation, Pseudomonas aeruginosa, Cystic Fibrosis Foundation, Staphylococcus, Risk, Valencia CF Foundation, Organization, Pneumonia, Drug resistance, Genetic disorder, Coronavirus, Genetic engineering, NTM, QIDP, Trial of the century, Mab, Immune system, Disease, VAP, Patient, Gallium, Pharmacokinetics, Pharmaceutical industry, Vaccine

Details of the CF Foundation’s equity investment are available in an 8-K filed with the US Securities and Exchange Commission on December 12, 2022.

Key Points: 
  • Details of the CF Foundation’s equity investment are available in an 8-K filed with the US Securities and Exchange Commission on December 12, 2022.
  • Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) protein.
  • Aridis Pharmaceuticals, Inc. discovers and develops novel anti-infective therapies to treat life-threatening infections, including anti-infectives to be used as add-on treatments to standard-of-care antibiotics.
  • The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.

Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Retrieved on: 
星期一, 十二月 12, 2022
Epitope, Security (finance), Bacteria, O11, Sale, ODD, Neutralizing antibody, National Institutes of Health, CF, Immunoglobulin G, Cystic fibrosis, Infection, Immunoglobulin M, COVID-19, Urinary tract infection, European Medicines Agency, EMA, Prevalence, S. aureus, US Foods, FDA, HAP, Safety, Staphylococcus aureus, CFTR, Inhalation, Pseudomonas aeruginosa, Cystic Fibrosis Foundation, Staphylococcus, Risk, Valencia CF Foundation, Organization, Pneumonia, Drug resistance, Genetic disorder, Coronavirus, Genetic engineering, NTM, QIDP, Trial of the century, Mab, Immune system, Disease, VAP, Patient, Gallium, Pharmacokinetics, Pharmaceutical industry, Vaccine

Details of the CF Foundation’s equity investment are available in an 8-K filed with the US Securities and Exchange Commission on December 12, 2022.

Key Points: 
  • Details of the CF Foundation’s equity investment are available in an 8-K filed with the US Securities and Exchange Commission on December 12, 2022.
  • Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) protein.
  • Aridis Pharmaceuticals, Inc. discovers and develops novel anti-infective therapies to treat life-threatening infections, including anti-infectives to be used as add-on treatments to standard-of-care antibiotics.
  • The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.